Why Partner

As bispecific and multispecific antibodies enter a new era of clinical validation and innovative design, biopharma teams face growing pressure to differentiate their programs, strengthen translational confidence, and accelerate development timelines. Despite rising investment and expanding modality diversity, significant challenges persist:

• Engineering and optimizing differentiated bispecific and multispecific formats
• Translating complex biology into predictive preclinical and assay strategies
• A growing need for specialized external expertise to accelerate discovery and development

The inaugural World Bispecific Europe Summit unites a technically focused audience of Europe’s bispecific decision-makers, creating a unique opportunity for partners to demonstrate how their solutions directly address these challenges. From antibody discovery and characterization to preclinical modelling and scalable manufacturing, this forum enables sponsors to position their expertise where demand is most acute, supporting bispecific programs as they move from concept through clinical development.